Upgrade to SI Premium - Free Trial

Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018

November 9, 2018 8:00 AM

Live Webcast to Begin at 8:30 a.m. Eastern Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.

The R&D Day will feature presentations by the following clinicians:

Dicerna’s management team will discuss the Company’s most advanced GalXC programs and future technology directions. Topics will include:

A live webcast of the Dicerna R&D Day and the full presentation will be available at 8:30 a.m. ET today on the Events & Presentations page in the Investors & Media section of the Dicerna website. A replay of the presentation will be available on the website within 48 hours.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between a target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. The Company has existing strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, and Boehringer Ingelheim. For more information, please visit www.dicerna.com.

Investors:

Rx Communications Group

Paula Schwartz, 917-322-2216

[email protected]

or

Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

[email protected]

Source: Dicerna Pharmaceuticals, Inc.

Categories

Press Releases